Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia - 1 May 2017

Lasocki Arian, Tsui Alpha, Gaillard Frank, Tacey Mark, Drummond Katharine, Stuckey Stephen

Abstract excerpt

Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was to validate the utility of MRI imaging features in predicting IDH1 mutations in glioblastomas. Pre-operative MRIs of new glioblastoma patients, consisting of at least FLAIR and T1-weighted post-contrast sequences,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Imaging

Share to Mutation

Share to Reproducibility of Results

Source

Identifiers

PMID: 28214089
DOI: 10.1016/j.jocn.2017.01.007

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.PMID 28214089Read ↗

Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.Semantic proximity Read ↗

Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.Semantic proximity Read ↗

Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.Semantic proximity Read ↗

Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.Semantic proximity Read ↗

Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.Semantic proximity Read ↗

IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.Semantic proximity Read ↗

Clinical and imaging characteristics of supratentorial glioma with IDH2 mutation.Semantic proximity Read ↗

Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.Semantic proximity Read ↗

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.Semantic proximity Read ↗

Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes.Semantic proximity Read ↗

Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.Semantic proximity Read ↗

IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.